Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - calcitriol -

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: gelatin; butylated hydroxyanisole; glycerol; iron oxide red; iron oxide yellow; titanium dioxide; medium chain triglycerides; butylated hydroxytoluene; maize starch; sorbitol; mannitol - for the management of established post-menopausal osteoporosis by increasing calcium absorption, elevating circulating levels of calcitriol, and reducing vertebral fracture frequency. for the prevention of corticosteriod-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. for the treatment of hypoclacamia in patients with uraemic osteodystrophy, hypoparathyroidism and vitamin d resistant rickets. indications as at 4 march 2004: rocaltrol is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of a traumatic fracture. rocaltrol is also indicated for the prevention of corticosteriod-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. rocaltrol is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphatemic rickets.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - calcipotriol, quantity: 20.5 microgram/g; betamethasone dipropionate, quantity: 264 microgram/g (equivalent: betamethasone, qty 205 microgram/g) - foam - excipient ingredients: polyoxypropylene-11 stearyl ether; liquid paraffin; dl-alpha-tocopherol; white soft paraffin; butane; methyl ether - enstilar is indicated for the topical treatment of psoriasis vulgaris in adults.

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - calcipotriol - cutaneous ointment - 50microgram/1gram

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - calcipotriol monohydrate - cutaneous solution - 50microgram/1ml

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

galderma laboratories, l.p. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 3 ug in 1 g - vectical ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in adults and pediatric patients 2 years and older. the safety and effectiveness of vectical ointment in patients with known or suspected disorders of calcium metabolism have not been evaluated. none risk summary available data from pregnancies that occurred during the clinical development of vectical ointment and published case series of oral and intravenous calcitriol use in pregnant women have not identified a drug associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes. in animal reproduction studies, topical administration of calcitriol to pregnant rabbits during the period of organogenesis resulted in an increased incidence of fetal deaths, as well as an increased incidence of minor skeletal abnormalities (see data) . the available data do not allow the calculation of relevant comparisons between the systemic exposures of calcitriol observed in animal studies to the

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

validus pharmaceuticals llc - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 0.25 ug - predialysis patients rocaltrol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. dialysis patients rocaltrol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, rocaltrol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. hypoparathyroidism patients rocaltrol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. rocaltrol should not be given to patients with hypercalcemia or evidence of vitamin d toxicity. use of rocaltrol in patients with known hypersensitivity to rocaltrol (or drugs of the same class) or any of the inactive ingredients is contraindicated.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 0.25 ug - predialysis patients rocaltrol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. dialysis patients rocaltrol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, rocaltrol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. hypoparathyroidism patients rocaltrol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism,

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - calcitriol, quantity: 0.5 microgram - capsule, soft - excipient ingredients: butylated hydroxyanisole; sorbitol solution (70 per cent) (non-crystallising); ascorbyl palmitate; iron oxide yellow; sodium ethyl hydroxybenzoate; sodium propyl hydroxybenzoate; medium chain triglycerides; gelatin; titanium dioxide; glycerol; iron oxide red

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: iron oxide red; sodium propyl hydroxybenzoate; medium chain triglycerides; ascorbyl palmitate; glycerol; butylated hydroxyanisole; titanium dioxide; sodium ethyl hydroxybenzoate; gelatin; sorbitol solution (70 per cent) (non-crystallising)